Transmission of drug-resistant HIV-1 variants among individuals with recent infection in Southern Poland

Current HIV Research

Volumn 11, Issue 4, 2013, Pages 288-294

  Smoleń Dzirba, Joanna ^a   Rosińska, Magdalena ^b   Kruszyński, Piotr ^a   Bratosiewicz Wasik, Jolanta ^a   Janiec, Janusz ^b   Beniowski, Marek ^c   Bociaga Jasik, Monika ^d   Jabłonowska, Elzbieta ^e   Szetela, Bartosz ^f   Wasik, Tomasz J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b NATIONAL INSTITUTE OF HYGIENE   (Poland)

^c Specialistic Hospital in Chorzów   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Drug resistance mutations; HIV 1; Pol gene; Transmission

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; POLAND; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS MUTANT; VIRUS MUTATION;

ADULT; ANTINEOPLASTIC AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENE FREQUENCY; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; POLAND; PREVALENCE;

EID: 84886072903     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162x113119990040     Document Type: Article

References (51)

1. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011; 365: 637-46.
2. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5: 140-55.
3. Booth CL, Geretti AM. Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 2007; 59: 1047-56.
4. Little SJ, Frost SDW, Wong JK, et al. Persistence of transmitted drugresistance among subjects with primary human immunodeficiency virus infection. J Virol 2008; 82: 5510-8.
5. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006; 41: 439-46.
6. Cane PA. Stability of transmitted drug-resistant HIV-1 species. Curr Opin Infect Dis 2005; 18: 537-42.
7. Fox J, Dustan S, McClure M, Weber J, Fidler S. Transmitted drugresistant HIV-1 in primary HIV-1 infection; incidence, evolution and impact on response to antiretroviral therapy. HIV Med 2006; 7: 477-83.
8. Neifer S, Somogyi S, Schlote F, Berg T, Poggensee G, Kuecherer C. Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. AIDS 2006; 20: 2231-3.
9. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40: 468-74.
10. Pao D, Andrady U, Clarke J, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570-3.
11. Baraboutis IG, Papastamopoulos V, Georgiou O, Skoutelis AT. Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Int J STD AIDS 2007; 18: 722-4.
12. Gandhi RT, Wurcel A, Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003; 37: 1693-8.
13. Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother 2011; 66: 1467-80.
14. The SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 2008; 22: 625-35.
15. Yerly S, Rakik A, De Loes S, et al. Switch to unusual amino acids at codon 215 of the HIV type 1 reverse transcriptase gene in seroconverters infected with zidovudine-resistant variants. J Virol 1998; 72: 3520-3.
16. Balduin M, Oette M, Däumer MP, Hoffmann D, Pfister HJ, Kaiser R. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure. J Clin Virol 2009; 45: 34-8.
17. Bansi L, Geretti AM, Dunn D, et al. Impact of transmitted drugresistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr 2010; 53: 633-9.
18. Geretti AM, Fox ZV, Booth CL, et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52: 569-73.
19. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
20. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197: 867-70.
21. Lai CC, Hung CC, Chen MY, et al. Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan. J Antimicrob Chemother 2012; 67: 1254-60.
22. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
23. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20: 21-8.
24. Poggensee G, Kücherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med 2007; 8: 511-9.
25. Violin M, Cozzi Lepri A, Velleca R, et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analogcontaining highly active antiretroviral therapy. AIDS 2004; 18: 227-35.
26. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-66.
27. Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11: 363-71.
28. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug resistant HIV is stabilizing in Europe. J Infect Dis 2009; 200: 1503-8.
29. Bannister WP, Cozzi-Lepri A, Clotet B, et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 2008; 48: 324-33.
30. Chaix ML, Descamps D, Wirden M, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS 2009; 23: 717-24.
31. de Mendoza C, Rodriguez C, Eiros JM, et al. Antiretroviral recommendations may influence the rate of transmission of drugresistant viruses. Clin Infect Dis 2005; 41: 227-32.
32. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug resistant variants. Antivir Ther 2004; 9: 375-84.
33. Smoleń J, Kruszyński P, Bratosiewicz-Wa{ogonek}sik J, Witor A, Wa{ogonek}sik TJ. Retrospective analysis of the HIV-1 reverse transcriptase inhibitors' resistance in Silesia, Poland. Med Sci Monit 2011; 17: 42-7.
34. Stańczak GP, Stańczak JJ, Firla{ogonek}g-Burkacka E, et al. Transmission of HIV-1 drug resistance among newly diagnosed patients in Poland. Przegl Epidemiol 2007; 61: 29-34.
35. Stańczak GP, Stańczak JJ, Marczyńska M, et al. Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008. J Med Virol 2010; 82: 1291-4.
36. Izopet J, Salama G, Pasquier C, et al. Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 478-83.
37. Stanford University: Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu. Last accessed: June 18th, 2012.
38. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724. doi:10.1371/journal.pone.0004724. Accessed: June 18th, 2012.
39. The World Health Organization 2009 list of mutations for surveillance of transmitted drug resistant HIV strains. Available at: http://hivdb.stanford.edu/pages/WHOResistanceList. html. Accessed: June 18th, 2012.
40. Rozanov M, Plikat U, Chappey C, Kochergin A, Tatusova T. A webbased genotyping resource for viral sequences. Nucleic Acids Res 2004; 32: 654-9.
41. HIV sequence database. Los Alamos National Laboratory. Available at: http://www.hiv.lanl.gov. Last accessed: June 14th, 2012.
42. Yerly S, von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS 2007; 21: 2223-9.
43. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19: 1819-25.
44. Reuter S, Oette M, Sichtig N, et al. Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort. J Med Virol 2011; 83: 187-95.
45. Simon V, Padte N, Murray D, et al. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol 2003; 77: 7736-45.
46. Ministry of Health: [Health program-Antiretroviral treatment for HIV infected persons in Poland, in the years 2010-2011]. Available at: http://www.mz.gov.pl/wwwfiles/ma_struktura/docs/program_aids_130 42011.pdf. Accessed: June 14th, 2012.
47. Smoleń-Dzirba J, Rosińska M, Kruszyński P, et al. Molecular epidemiology of recent HIV-1 infections in southern Poland. J Med Virol 2012; 84: 1857-68.
48. Johnson VA, Calvez V, Günthard HF, et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-64.
49. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by cross-sectional survey for use in low resource settings. Antivir Ther 2008; 13: 37-48.
50. Marinda ET, Hargrove JW, Preiser W, et al. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 53: 496-9.
51. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drugresistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693-701.